High-priced drugs used to treat diabetic macular edema not cost-effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news

Bevacizumab offers best value of anti-VEGF drugs to treat DME
Despite recent data showing that aflibercept is the most effective anti–vascular endothelial growth factor (anti-VEGF) treatment available for patients with diabetic macular edema, bevacizumab is... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 9, 2016 Category: Endocrinology Source Type: news

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Media News)
Source: Roche Media News - June 8, 2016 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2016 Category: Pharmaceuticals Source Type: news

Duke’s Poliovirus Therapy Shows Survival Benefit in Early Patients
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org ASCO Abstract #2061 FOR IMMEDIATE RELEASE on Monday, June 6, 2016  DURHAM, N.C. – An early group of patients who received a modified form of the poliovirus to treat recurrent glioblastoma brain tumors showed survival improvement over historical controls, according to researchers at the Preston Robert Tisch Brain Tumor Center at Duke Health. The findings, which have not been peer reviewed, were presented at the American Society of Clinical Oncology annual meeting in Chicago (ASCO abstract #2061).  “At the fi...
Source: DukeHealth.org: Duke Health Features - June 6, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreate...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news

New Data Evaluating KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed over...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news

Radiation therapy with pembrolizumab, bevacizumab safe for glioma patients
Researchers will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 4, 2016 Category: Science Source Type: news

Moffitt: Radiation therapy with pembrolizumab, bevacizumab safe for glioma patients
(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2016 Category: Global & Universal Source Type: news

Delhi High Court asks Roche to explain lawsuit over Avastin copy
Roche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to bevacizumab. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 24, 2016 Category: Pharmaceuticals Source Type: news

Chugai announcement: Avastin approved for additional indication of advanced or recurrent cervical cancer
(Source: Roche Investor Update)
Source: Roche Investor Update - May 24, 2016 Category: Pharmaceuticals Source Type: news

Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil Sibal
The judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2016 Category: Pharmaceuticals Source Type: news

Newer Drugs Helping Older People With Eye Disease
FRIDAY, May 20, 2016 -- New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates. The drugs Avastin and Lucentis have significantly increased the number of people with AMD... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2016 Category: Journals (General) Source Type: news

Roche moves court to block copies of cancer drug Avastin, A La Herceptin
Roche has challenged the regulator and pleaded to block the approvals of the drugs under review, ET learned from highly placed legal sources. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 16, 2016 Category: Pharmaceuticals Source Type: news

Long-term benefits of age-related macular degeneration treatments
A 5-year follow-up study confirmed the long-term benefits of using the drugs Avastin and Lucentis to treat age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 10, 2016 Category: Consumer Health News Source Type: news

Advanced Breast Cancer Slowed with Avastin Combo (CME/CE)
(MedPage Today) -- But with more toxicity, no overall survival benefit (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 5, 2016 Category: Hematology Source Type: news

Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news

CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 25, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Questions surface about Palmaz Scientific’s fundraising Palmaz Scientific, which filed for Chapter 11 bankruptcy protection last month, is reportedly embroiled in a dispute with Jefferies & Co. over its claim that the...
Source: Mass Device - April 25, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

FDA grants IDE to NovoCure for phase II Optune trial
NovoCure (NSDQ:NVCR) said today that Radiation Therapy Oncology Group Foundation won FDA investigational device exemption to conduct a Phase II pilot test of NovoCure’s Optune in conjunction with bevacizumab to treat bevacizumab-refractory recurrent glioblastoma. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. “This is the 1st consortium study of TTFields, representing a growing interest in TTFields therapy from the scientifi...
Source: Mass Device - April 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Oncology NovoCure Source Type: news

Lifetime Achievement Award Finalists Announced
FINALIST: Freda C. Lewis-Hall, Medical Officer and Executive Vice President, Pfizer Before joining Pfizer in 2009, Lewis-Hall held senior leadership positions in medical affairs and new product development with Vertex, Bristol Myers Squibb, Pharmacia and Lilly. Lewis-Hall actually started her career outside of pharma working in front-line mental health services for families and communities. A passionate advocate for empowering patients through knowledge, she speaks frequently in venues from TEDMED to the Essence Music Festival, appears regularly on television shows including The Doctors and Dr. Phil, and shares health and ...
Source: EyeForPharma - April 22, 2016 Category: Pharmaceuticals Authors: Thomas Disley Source Type: news

AMD: Untreated Sleep Apnea May Reduce Response to BevacizumabAMD: Untreated Sleep Apnea May Reduce Response to Bevacizumab
A small, single-center study has suggested untreated sleep apnea reduces treatment response to bevacizumab in patients with exudative age-related macular degeneration. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 14, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Combo Tx Slows Prostate Cancer Relapse (CME/CE)
(MedPage Today) -- ADT plus bevacizumab for hormone-sensitive disease (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 6, 2016 Category: Geriatrics Source Type: news

Aflibercept for Macular Edema Secondary to Central RVOAflibercept for Macular Edema Secondary to Central RVO
Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Real-World Results With Bevacizumab for DME Doesn't Match Trial ResultsReal-World Results With Bevacizumab for DME Doesn't Match Trial Results
In the real world, intravitreal bevacizumab (IVB) for diabetic macular edema (DME) doesn't work as well as it does in clinical trials, according to new research. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 22, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Drug Used for Preemie Eye Disease Tied to Disabilities
Babies given Avastin were far more likely to have neurological complications, study shows (Source: U.S. News - Health)
Source: U.S. News - Health - March 18, 2016 Category: Consumer Health News Source Type: news

Drug Used for Preemie Eye Disease Tied to Disabilities
Babies given Avastin were far more likely to have neurological complications, study shows Source: HealthDay Related MedlinePlus Pages: Medicines, Premature Babies, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 18, 2016 Category: Consumer Health News Source Type: news

Drug Used for Preemie Eye Disease Tied to Problems
Babies given Avastin were far more likely to have neurological complications, study shows (Source: WebMD Health)
Source: WebMD Health - March 18, 2016 Category: Consumer Health News Source Type: news

Drug Used for Preemie Eye Disease Tied to Disabilities
FRIDAY, March 18, 2016 -- A drug used to treat an eye disease in premature infants may be linked to serious disabilities such as cerebral palsy and hearing loss, a new study suggests. The drug in question is Avastin (bevacizumab), a cancer drug that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 18, 2016 Category: Journals (General) Source Type: news

Bevacizumab May Increase Risk for Motor Deficits in PreemiesBevacizumab May Increase Risk for Motor Deficits in Preemies
According to a new study in infants with ROP, intravitreal bevacizumab treatment increases the risk for motor impairment at age 18 months compared with laser treatment alone. Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 17, 2016 Category: Intensive Care Tags: Pediatrics News Source Type: news

Tracon begins dosing in Phase Ib trial of lung cancer drug candidate TRC105
US-based Tracon Pharmaceuticals has begun a Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, in combination with Avastin (bevacizumab), and carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer (… (Source: Drug Development Technology)
Source: Drug Development Technology - March 15, 2016 Category: Pharmaceuticals Source Type: news

Indian drug regulator backs off over use of Roche’s Avastin
The Drug Controller General of India has passed an order removing an alert notice for the use of Roche’s Avastin (bevacizumab) injection to treat age-related degeneration. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 12, 2016 Category: Pharmaceuticals Source Type: news

Aflibercept Best in Diabetics With Bad Baseline Vision? Aflibercept Best in Diabetics With Bad Baseline Vision?
Final results from a trial comparing aflibercept, bevacizumab, and ranibizumab in diabetic macular edema confirm all three drugs are similar, but aflibercept is best in those with worse baseline vision, says lead researcher. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

New drug outperforms standard diabetic vision loss treatments
Stephen FellerBETHESDA, Md., Feb. 29 (UPI) -- In a trial, Eylea outperformed Avastin at returning vision for some diabetic macular edema patients, and about as well as other drugs for most patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 29, 2016 Category: Consumer Health News Source Type: news

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 29, 2016 Category: American Health Source Type: news

Study Compares Drugs for Common Diabetic Eye Disease
MONDAY, Feb. 29, 2016 -- People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease -- Avastin, Eylea and Lucentis -- vary widely in price, but new research... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 29, 2016 Category: Journals (General) Source Type: news

Research on treatments for advanced ovarian cancer
New research supports the use of weekly chemotherapy without bevacizumab in treating advanced ovarian cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 26, 2016 Category: Science Source Type: news

Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis (ranibizumab), contrary to year-one results from the study, which showed Eylea with a clear advantage. Language English (Source: News from NEI)
Source: News from NEI - February 25, 2016 Category: Opthalmology Authors: Jason Source Type: news

Roche begins probe into Avastin use for eye ailments
Roche has initiated an internal investigation following reports the it had been used in certain eye ailments and damaged the vision of 15 patients in Gujarat. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 23, 2016 Category: Pharmaceuticals Source Type: news

India issues alert to deter use of Roche's Avastin drug for eyes
NEW DELHI (Reuters) - India's federal drugs controller issued an alert on Thursday, asking states to ensure Swiss drugmaker Roche's cancer treatment Avastin was not administered to treat eyes, after its usage hampered vision in 15 patients. (Source: Reuters: Health)
Source: Reuters: Health - January 21, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Bevacizumab for ROP May Trigger Hypotension in PreemiesBevacizumab for ROP May Trigger Hypotension in Preemies
Intravitreal bevacizumab therapy for retinopathy of prematurity should be used with caution, as it might lead to hypotension in premature infants, a recent case study showed. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Using Bevacizumab in High-Risk Cervical Cancer Using Bevacizumab in High-Risk Cervical Cancer
Dr Maurie Markman discusses a paper showing that bevacizumab significantly improves overall survival rates in high-risk cervical cancer patients. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2016 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Indian States Halt Off-Label Use of Roche Avastin
India's Gujarat and Telangana states halted sales of Roche's blockbuster drug Avastin, after it hampered the vision of 15 patients who used it for a condition it had not been FDA-approved to treat. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 20, 2016 Category: Pharmaceuticals Source Type: news

Two Indian states halt sales of Roche's Avastin drug
NEW DELHI (Reuters) - Two Indian states have put sales of Swiss drugmaker Roche's blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat. (Source: Reuters: Health)
Source: Reuters: Health - January 19, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

No Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: StudyNo Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: Study
Intravitreal bevacizumab does not alter the long-term outcomes of neovascular glaucoma (NVG), so panretinal photocoagulation (PRP) should remain the mainstay of treatment, according to a retrospective study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 11, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Slippery Slope: Is Afinitor for Breast Cancer Avastin Redux?
(MedPage Today) -- The FDA reversed itself on Avastin for breast cancer, but Afinitor is a different story (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 13, 2015 Category: American Health Source Type: news

New Regulatory Requirements Tied to Drop in Intravitreal Bevacizumab UseNew Regulatory Requirements Tied to Drop in Intravitreal Bevacizumab Use
Regulations requiring patient-specific prescriptions (PSPs) for drugs used off-label may have caused a drop in prescriptions for intravitreal bevacizumab, with retinal specialists switching to medications that don't require PSPs, according to a study from Ohio. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 30, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Bevacizumab May Improve Surgical Outcomes in Advanced Gastric CancerBevacizumab May Improve Surgical Outcomes in Advanced Gastric Cancer
Bevacizumab may help improve surgical outcomes in locally advanced gastric cancer (LAGC), new research from China suggests. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival
Bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage, report scientists. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 23, 2015 Category: Science Source Type: news